Need to clarify & very clear It was stated , that you are tired of Matt running his own or Onc going it alone.
Plain language, ONC has never eluded, suggested or indicated they would be doing a phase 3 trial alone.
Since Day one ( articles of incorporation & founding business plan).
oncolytics biotech is a start up pharma company. Only goal to to prove Pelareorep is able yo get to market.
That will require a license deal, partnership and/ or sale of the company.
It has been discussed many times at KOL & general updates.
" The cost of phase 3 trial is prohibitive for ONC to proceed without big pharma assistance"
Andrew G, now gone, mentioned the estimated cost to move through a phase 3, get approval & market a product is " about" a $300million comitment.
That number would be on top of aquiring Onc.
So why so long. Roche or others need a solid strength of their decision to proceed.
From ONc perspective?
imho they have never been in such a strong clinical position.
MBc cancer phase 3 & MBc phase 3..both with FDA fast track approval.
Add in a few other side trials, all looking solid.
Problem?
They need both operating $$ and a partner to get to next level.
Reminds me of Nicola Tesla. Way back he had a contract with Westinghouse.
He was to receive infinte royalties based on every KW rating of electrical devices using his patented phase 3 A/c power.
in todsys $, he would have been wealthier than even the richest billionaires of today.
What happened?
There was a recession, Westinghouse & others were hurting. The banks did not welcome the royalty load, on top of failing bottom lines.
Nickola Tesla had the best patitent, the best proven technology of the time, yet the buisiness world was not in favour if his success.
He was bought out, for YES a very large sum. Howevr a fraction of the long term potentioal.
Why the comparison?
IMHO Pelareorep is within a notch of getting to market.
pelareorep, might be the very best option. Proven safe,
iV delivery, does not require special handling. It finds the cancer.
Does it work? The recent pancreatic cancer trial with Roche generated results that in if them selves were block buster.
Creating a very fast progress to FDA approval to proceed to phase 3 trial.
Regretably the PanCan cancellation out the breaks on that progress.
So they are in a $$ squeeze. Terrible timing.
Moving forward, something $$ needs to be done.
everybody knows that.
Investors, analysts, Onc management, potential pharma parteners,
What ever $$ deal comes forward, let's hope for the best.
again. Complete sale, partership, or a complete reorganization of the business model.
id like to bookend as I started.
Onc is not & can not do a phase 3 trial alone.
One caveat to that statement; in its existing business model.
stay tuned.